Navigation Links
Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer
Date:10/29/2007

GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc., which discovers and develops novel antiviral therapeutics as well as pharmacokinetic enhancers, announced today the appointment of Steven D. Skolsky as its President and Chief Executive Officer. He will also serve as a member of the Board of Directors.

"Sequoia is pleased to have recruited such an outstanding, talented leader as Steven Skolsky," said Chris Mirabelli, Chairman of the Board of Sequoia Pharmaceuticals. "Steve has an impressive record of success within the pharmaceutical industry. The combination of his leadership and management experience, as well as his business acumen, makes Steve uniquely qualified to lead us through the exciting times ahead."

"Sequoia possesses an extraordinary scientific pedigree, and a very attractive research portfolio. I am honored to have the opportunity to lead Sequoia, and to build on its outstanding technological progress as we move towards commercialization", said Mr. Skolsky.

Mr. Skolsky brings over twenty-five years of U.S. and international experience in the pharmaceutical and biotechnology arena. He most recently served as chief executive officer of Trimeris, a biotechnology company specializing in HIV therapeutics. Previously Mr. Skolsky had a distinguished career at GlaxoSmithKline where he served as GSK's Senior Vice President of Global Commercial Strategy responsible for world-wide clinical development and product strategy. He also served as managing director of GSK's operations in Australia and New Zealand and previously was Vice President of Sales and Marketing of the HIV/Oncology Division at Glaxo Wellcome. He is a graduate of the University of North Carolina at Chapel Hill.

About Sequoia Pharmaceuticals, Inc.

Sequoia Pharmaceuticals discovers and develops revolutionary new treatments, primarily for viral diseases including HIV/AIDS and HCV-induced hepatitis. In addition, Sequoia has an active R&D program in pharmacokinetic enhancers.


'/>"/>
SOURCE Sequoia Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by ... congenital diaphragmatic hernia have better survival rates if surgery is performed early. Approximately ... where the diaphragm fails to form completely, letting abdominal organs into the chest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... Massachusetts , April 27, 2016 ... that Jeff Poulton , Chief Financial Officer, will present ... Boston, MA on Wednesday, May 04, ... audio webcast will be available on the Presentations and Webcasts ... a replay of the webcast will be available on this ...
Breaking Medicine Technology: